Drug Trial Radar · NCT05018221
Better Evidence and Translation for Calciphylaxis
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Aug 26, 2021
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- University of SydneyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Australasian Kidney Trials Network; Northern Care Alliance NHS Foundation Trust; Waitemata District Health Board; Vantive Health LLC; Berry Consultants
- First posted
- Aug 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This global platform study will evaluate multiple interventions, across several domains of therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.
Conditions
- Calciphylaxis
Interventions
Vitamin K1Drug
Vitamin K1 capsule (10mg) to be administered 3 times per week following the subject's hemodialysis session.
Magnesium citrateDrug
Magnesium Citrate tablet (150mg) to be administered 3 times per per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
Sodium ThiosulfateDrug
Sodium Thiosulfate injection (25g/100ml) to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
High Flux DialyserDevice
Hemodialysis using a high flux dialyser.
Medium Cut-off DialyserDevice
Hemodialysis using a medium cut-off dialyser.
Placebo injection (normal saline)Drug
Placebo to be administered intravenously 3 times per week, during the subject's last hour of hemodialysis.
Placebo capsule (Vitamin K1)Drug
Placebo to be administered 3 times per week following the subject's hemodialysis session.
Placebo tablet (Magnesium citrate)Drug
Placebo to be administered 3 times per day. On dialysis days, administration of the middle daily dose should occur following the subject's hemodialysis session.
Primary outcomes
What the sponsor says the trial is designed to measure.
- BEAT-Calci Wound Assessment Scale (BCWAS) - Baseline to Week 12Time frame: Week 12
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
Royal Adelaide Hospital
Adelaide, Australia · Recruiting
Monash Medical Centre
Clayton, Australia · Recruiting
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Recruiting
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
John Hunter Hospital
New Lambton Heights, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Sunshine Coast Hospital and Health Service
Birtinya, Queensland, Australia · Recruiting
Princess Alexandra Hospital
Brisbane, Queensland, Australia · Recruiting
Bundaberg Base Hospital
Bundaberg, Queensland, Australia · Recruiting
Cairns Hospital
Cairns, Queensland, Australia · Recruiting
Townsville Hospital
Douglas, Queensland, Australia · Recruiting
Ipswich Hospital
Ipswich, Queensland, Australia · Recruiting
Royal Melbourne Hospital
Melbourne, Victoria, Australia · Recruiting
Sunshine Hospital (Western Health)
St Albans, Victoria, Australia · Recruiting
Royal Perth Hospital
Perth, Western Australia, Australia · Recruiting
Dunedin Hospital
Dunedin, New Zealand · Recruiting
Auckland City Hospital (Auckland DHB)
Grafton, New Zealand · Recruiting
North Shore Hospital (Waitemata DHB)
Takapuna, New Zealand · Recruiting
Tauranga Hospital
Tauranga, New Zealand · Recruiting
Whangarei Hospital
Whangarei, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.